Olivier Rixe
Hematology & Oncology · Albuquerque, NMNPI 1255568721
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.4% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $694 and has fallen 97.4% since, to $18 in 2023. That places this record below the midpoint for hematology & oncology clinicians in NM, where the typical reported total is $2,649.
Across 101 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$284
- Seagen Inc.$216
- AstraZeneca$128
- Johnson & Johnson$95
- Novartis$87
- Amgen$85
- plus $715 from 25 others
Across 164 payments — averaging $9674.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$736K
- Daiichi Sankyo Inc.$647K
- Kyowa Kirin, Inc.$123K
- Kyowa Kirin Pharmaceutical Development, Inc$64K
- Amgen$6K
- AstraZeneca$6K
- plus $4K from 2 others
What the payments were for
- Food & beverage$1,48792%
- Education$1228%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 19 | $284 |
| Seagen Inc. | 14 | $216 |
| AstraZeneca | 8 | $128 |
| Johnson & Johnson | 6 | $95 |
| Novartis | 6 | $87 |
| Amgen | 4 | $85 |
| Merck | 6 | $67 |
| Puma Biotechnology, Inc. | 4 | $57 |
| Eisai Inc. | 3 | $56 |
| Novocure Inc. | 1 | $51 |
| Incyte Corporation | 3 | $49 |
| Rigel Pharmaceuticals, Inc. | 2 | $40 |
| Karyopharm Therapeutics Inc. | 2 | $38 |
| Gilead | 2 | $36 |
| Sanofi | 2 | $33 |
| Agios Pharmaceuticals, Inc. | 2 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Lilly USA, LLC | 1 | $24 |
| Taiho Oncology, Inc. | 2 | $24 |
| Bayer | 2 | $24 |
| AbbVie | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| EMD Serono, Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Advanced Accelerator Applications | 1 | $12 |
| Exelixis Inc. | 1 | $12 |
| Acrotech Biopharma Inc. | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
| Clovis Oncology, Inc. | 1 | $7 |
How this compares
$1,609 in reported general payments places this provider in the 40th percentile of 54 hematology & oncology providers in New Mexico.
Other hematology & oncology in Albuquerque
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- George AtwehAlbuquerque$24K
- Scott HerbertAlbuquerque$14K
- Jose AvitiaAlbuquerque$11K
- Zoneddy DayaoAlbuquerque$10K
- Toufic TannousAlbuquerque$10K
- Amy TarnowerAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.